Sponsor Overview
Explore verified public information about SCYNEXIS, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria SCYNEXIS is committed to making Investigational Products available to seriously ill patients who have exhausted other treatment options. A treating physician, who is able to comply with the SCYNEXIS requirements, may request information about how to apply for access to SCYNEXIS’ Investigational Products by contacting the company. Available Therapies via Single-Patient EA SCY-078 is a triterpenoid, glucan synthase inhibitor, antifungal agent undergoing investigation for: • The treatment of invasive candidiasis, including candidemia (IC). • The treatment of invasive aspergillosis (IA), including IA that is refractory to or intolerant of other antifungal therapies. • The treatment of invasive candidiasis in patients who are refractory to or intolerant of other antifungal therapies.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.